CHOSA (RHOVAC BTA)

Chosa Oncology, Danish -Swedish biotechnology company, has developed the iCIP platform, which includes a liposomal formulation of cisplatin (LiPlaCis) and the companion diagnostic (DRP) tool detecting patients who benefits the most of the cisplatin treatment. The recently achieved clinical phase 2b results mean that the Company is now gearing up the business development activities to find partners for partnership or trade deal.

Quotes for CHOSA Oncology AB

Right Now

+/-
%
Latest
High
Low
Volume
Turnover ()
Time (Latest trade)

Board

CEO

Peter Buhl

Chairperson of the Board

Ingrid Atteryd Heiman

Board

Claus Frisenberg Pedersen
Fred Hirsch
Morten Myrhøj
Neil Goldsmith
Ulla Hald Buhl

Articles of association

News

News agencies

2025-03-26 14:32:41 Finwire: Chosa Oncology ska presentera data för cisplantin-respons i slutet av Q2
2025-02-28 08:52:54 Finwire: Chosa Oncology rapporterar ökad rörelseförlust
2025-02-10 11:10:44 Finwire: Chosa Oncology ingår samarbete med lungcancerexperter
2024-11-11 08:37:11 Finwire: Chosa Oncology ökar förlusten
2024-08-30 08:58:20 Finwire: Chosa Oncology minskar förlusten

Analysis

Largest Owners

Name	Capital %	Votes %	Date
Buhl Krone Holding ApS	22,04	22,04	2025-03-27
Claus Frisenberg Pedersen	11,68	11,68	2023-01-18
IPO Nordic Fund A/S	8,36	8,36	2025-03-27
Smerud Medical Research International AS	7,48	7,48	2025-03-27
Rutger Arnhult	5,48	5,48	2025-03-27
Nels Holding Aps	4,00	4,00	2025-03-27
Lh\|Lh Invest Aps	2,97	2,97	2025-03-27
Karsgaard Holding Ostervra Aps	2,36	2,36	2025-03-27
Sorgenfri Nr. 1 A/S	2,17	2,17	2025-03-27
Rq Solutions Aps	1,87	1,87	2025-03-27

** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

*Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

CHOSA Oncology AB